Drugs /

s81694

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for s81694

S81694 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating s81694, 1 is phase 1/phase 2 (0 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for s81694 clinical trials.

Breast carcinoma is the most common disease being investigated in s81694 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating S81694
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating s81694 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.